

Supplementary file 1 - eMethods

eMethod 1 - Eligibility criteria for the study

eMethod 2 - Search strategy for the study

eMethod 1 - Eligibility criteria for the study

Inclusion criteria:

1. Adults both males and females aged 18 and more than 18 years undergoing haemodialysis or peritoneal dialysis receiving antihypertensive medication.
2. Randomized controlled trials with individual and cluster type, observational studies.
3. Studies that assessed the effects of ARB on blood pressure.
4. Studies that assessed other antihypertensive agents (Calcium channel blocker, alpha and beta blocker, diuretic) or placebo.
5. Studies in English, or studies that can be translated to English.

Exclusion criteria:

1. Paediatric age group <18 years
2. Editorials, guidelines
3. Commentary reports, Case reports <5 patients
4. Abstracts with no full text available
5. Letters to editors
6. Animal and cadaveric studies

eMethod 2 - Search strategy for the study

PubMed search

No	Terms used	Data
#1	"Renal Dialysis"[Mesh] OR "Hypertension, Renal"[Mesh] OR "post dialysis hypertension*" [tw]	142,221
#2	"Losartan"[Mesh] OR Losartan*[tw]	10,448
#3	"Antihypertensive Agents"[Mesh] OR "High BP treatment*" [tw] OR "High BP management*" OR "Hypertension management*" [tw] OR "Anti-hypertensive agent*" [tw] OR "Drugs, Anti-Hypertensive" [tw] OR "Antihypertensive Drug*" [tw] OR "Agents, Anti-Hypertensive" [tw]	77,672
#4	#1 AND #2	247
#5	#1 AND #3	2939
#6	#1 AND #2 AND #3	140
#7	#2 AND #3	3137
#8	#7 OR #1	145,218

Cochrane search

- #1 MeSH descriptor: [Hypertension, Renal] explode all trees 271
#2 MeSH descriptor: [Renal Dialysis] explode all trees 5570
#3 MeSH descriptor: [Losartan] explode all trees 1301
#4 MeSH descriptor: [Antihypertensive Agents] explode all trees 8399
#5 #1 AND #2 15
#6 #3 AND #4 AND #5 0
#7 #3 AND #4 OR #5 640
#8 #3 AND #4 625

Supplement file 2

eTable 1 - NIH quality assessment for the included studies in the systematic review (N = 13)

eFigure 1 - Publication bias of the included studies in post-dialysis for the systolic and diastolic blood pressure (SBP and DBP) among the included studies for the review.

eFigure 2 - Publication bias of the included studies in post-dialysis for the systolic and diastolic blood pressure (SBP and DBP) with losartan and other ARB agents among the included studies for the review.


eFigure 3 - Sensitivity analysis of the included studies in post-dialysis for the SBP and DBP (A study with less than 30 study population were excluded for their analysis)

eTable 1 - NIH quality assessment for the included studies in the systematic review (N = 13)


Author and year	NIH Quality assessment (Bias)	NIH Quality assessment (Bias) supporting text
Huber M et al, ²⁹ 2013	Medium	Drop out was high
Takahashi A et al, ²⁷ 2006	Low	
Aftab RA et al, ²⁵ 2017	Low	
Mitsuhashi H et al, ¹⁵ 2009	Medium	No blinding mentioned
Shigenaga A et al, ³³ 2009	Low	
Bikos A et al, ²⁸ intradialytic, and ambulatory BP in patients with intradialytic hypertension. Methods: This is a pilot randomized-cross-over study in 38 hemodialysis patients (age: 60.4 ± 11.1 years, men: 65.8% 2018	Low	
Iino Y et al, ³⁶ 2003	Low	
Suzuki H et al, ³⁵ and is highly predictive of future cardiac morbidity and mortality. In patients with hypertension and LVH, both an angiotensin converting enzyme (ACE 2004	Medium	Blinding not done
Iseki K et al, ³¹ but there is uncertainty surrounding the effects of blood pressure (BP 2013	Medium	Blinding and allocation concealment not done
Ichihara A et al, ³⁰ 2005	Medium	Blinding and allocation concealment not done
Suzuki H et al, ³⁴ their effect in patients with kidney failure on HD therapy is not known. Study Design: Open-labeled randomized trial. Setting & Participants: Patients aged 30 to 80 years receiving HD 2 to 3 times weekly for 1 to 5 years at 5 university-affiliated dialysis centers. Interventions: Treatment with ARBs (valsartan, candesartan, and losartan 2008	Medium	Blinding not done
Peters CD et al, ²⁶ but whether they exert beneficial cardiovascular effects is unclear. Here the long-term effects of the angiotensin II receptor blocker, irbesartan, were studied in hemodialysis patients in a double-blind randomized placebo-controlled 1-year intervention trial using a predefined systolic blood pressure target of 140mmHg (SAFIR study 2015	Low	
Kayabasi H et al, ³² 2013	Low	

eFigure 1: Publication bias of the included studies in post-dialysis for the systolic and diastolic blood pressure (SBP and DBP) among the included studies for the review.

eFig 1(a): Systolic blood pressure



eFig 1(b): Diastolic blood pressure



eFigure 2: Publication bias of the included studies in post-dialysis for the systolic and diastolic blood pressure (SBP and DBP) with losartan and other ARB agents among the included studies for the review.

eFig 2(a): Systolic blood pressure






Fig 2(b): Diastolic blood pressure



eFigure 3: Sensitivity analysis of the included studies in post-dialysis for the SBP and DBP (A study with less than 30 study population were excluded for their analysis)

eFig 3(a): Systolic blood pressure



eFig 3(b): Diastolic blood pressure

